Home
Search Center
Journal List
CMA
Contact US
|
Chinese
You Position:
Home
> Paper
Experience in treating a case of the cardiac rupture during transcatheter aortic valve implantation procedure
( views:0, downloads:0 )
Author:
No author available
Journal Title:
Chinese Medical Journal
Issue:
20
DOI:
10.1097/CM9.0000000000001098
Key Word:
No keyword available
Abstract: No abstract available
Reference
[1]Ling-Yu Li,Hong Wang,XIAO Chen,etc.
First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer:a cost-effectiveness analysis from China
[J].2019,(23).
[2]Jenkins, Russell W.,Barbie, David A.,Flaherty, Keith T..
Mechanisms of resistance to immune checkpoint inhibitors
[J].2018,118(1).
[3]Hellmann, Matthew D.,Callahan, Margaret K.,Awad, Mark M.,etc.
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer (vol 33, pg 853, 2018)
[J].2019,35(2).
[4]Khaltaev Nikolai,Axelrod Svetlana.
Global lung cancer mortality trends and lifestyle modifications: preliminary analysis
[J].2020,133(13).
[5]Anagnostou, Valsamo,Forde, Patrick M.,White, James R.,etc.
Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
[J].2019,79(6).
[6]Suresh, Karthik,Psoter, Kevin J.,Voong, Khinh Ranh,etc.
Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy
[J].2019,14(3).
[7]Takayuki Shiroyama,Hidekazu Suzuki,Motohiro Tamiya,etc.
Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab‐treated patients with advanced non–small cell lung cancer
[J].2018,7(1).
[8]Wadsworth, Catherine,Gray, Jhanelle E.,Dennis, Phillip A.,etc.
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
[J].2018,19(4).
[9]Shirish M. Gadgeel,Nathan A. Pennell,Mary Jo Fidler,etc.
Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC)
[J].2018,13(9).
[10]Jin, Sheng,Wenfeng, Fang,Juan, Yu,etc.
Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer.
[J].2016.
[11]Lilla, Hornyák,Nikoletta, Dobos,Gábor, Koncz,etc.
The Role of Indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy.
[J].2018,9(Spec ).
[12]Sung Won,Lim,Myung-Ju,Ahn.
Carcinoma, non-small-cell lung%Immune checkpoint inhibitor%Immunotherapy
[J].2018,34(1).
[13]Gulley, James L.,Rajan, Arun,Spigel, David R.,etc.
Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial
[J].2017,18(5).
[14]Gibney, Geoffrey T.,Weiner, Louis M.,Atkins, Michael B..
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
[J].2016,17(12).
[15]Rittmeyer, Achim,Barlesi, Fabrice,Waterkamp, Daniel,etc.
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
[J].2017,389(10066).
[16]Ozaki, Yuki,Muto, Satoshi,Takagi, Hironori,etc.
Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer
[J].2020,69(1).
[17]Chaput, N.,Lepage, P.,Coutzac, C.,etc.
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab
[J].2017,28(6).
[18]Fucà Giovanni,Galli Giulia,Poggi Marta,etc.
Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy
[J].2018,13(6).
[19]Wu, Qing,Liu, Junjin,Zhang, Yanhong,etc.
Predictive value of positron emission tomography for the prognosis of immune checkpoint inhibitors (ICIs) in malignant tumors
[J].2020,69(6).
[20]Barlesi, Fabrice,Vansteenkiste, Johan,Spigel, David,etc.
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study
[J].2018,19(11).
[21]Kim, Hyojin,Kwon, Hyun Jung,Han, Yeon Bi,etc.
Increased CD3+T cells with a low FOXP3+/CD8+T cell ratio can predict anti-PD-1 therapeutic response in non-small cell lung cancer patients
[J].2019,32(3).
[22]Brittany B, Campbell,Nicholas, Light,David, Fabrizio,etc.
Comprehensive Analysis of Hypermutation in Human Cancer.
[J].2017,171(5).
[23]Jin, Yueping,Dong, Hui,Xia, Liliang,etc.
The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC
[J].2019,14(8).
[24]Katsurada, Masahiro,Nagano, Tatsuya,Tachihara, Motoko,etc.
Baseline Tumor Size as a Predictive and Prognostic Factor of Immune Checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer
[J].2019,39(2).
[25]Georgios, Tsakonas,Simon, Ekman.
Oncogene-addicted non-small cell lung cancer and immunotherapy.
[J].2018,10(Suppl 13).
[26]Nataly,Manjarrez-Ordu?o,Laurence C,Menard,Selena,Kansal,etc.
Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer.
[J].2018,9.
[27]Ana,Bocanegra,Gonzalo,Fernandez-Hinojal,Miren,Zuazo-Ibarra,etc.
PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer.
[J].2019,20(7).
[28]Mekki, Ahmed,Dercle, Laurent,Lichtenstein, Philip,etc.
Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1
[J].2018,96.
[29]Andrea,Botticelli,Pamela,Vernocchi,Federico,Marini,etc.
Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment.
[J].2020,18(1).
[30]Joseph, Richard W.,Elassaiss-Schaap, Jeroen,Kefford, Richard,etc.
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
[J].2018,24(20).
[31]Berner, Fiamma,Bomze, David,Diem, Stefan,etc.
Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer
[J].2019,5(7).
[32]Luksza, Marta,Riaz, Nadeem,Makarov, Vladimir,etc.
A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy
[J].2017,551(Nov.23 TN.7681).
[33]Niemeijer, Anna-Larissa Nadia,Sahba, Sara,Smit, Egbert Frederik,etc.
Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy
[J].2020,123(3).
[34]Ricciuti, Biagio,Genova, Carlo,De Giglio, Andrea,etc.
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis
[J].2019,145(2).
[35]Naqash, Abdul Rafeh,Ricciuti, Biagio,Owen, Dwight H.,etc.
Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort
[J].2020,69(7).
[36]Peters, Solange,Gettinger, Scott,Johnson, Melissa L.,etc.
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)
[J].2017,35(24).
[37]Kluger, Harriet M.,Zito, Christopher R.,Turcu, Gabriela,etc.
PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors
[J].2017,23(15).
[38]Gandhi, L.,Rodriguez-Abreu, D.,Gadgeel, S.,etc.
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
[J].2018,378(22).
[39]Castello Angelo,Toschi Luca,Rossi Sabrina,etc.
The immune-metabolic-prognostic index and clinical outcomes in patients with non-small cell lung carcinoma under checkpoint inhibitors
[J].2020,146(5).
[40]David R. Spigel,Jamie E. Chaft,Scott Gettinger,etc.
FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC
[J].2018,13(11).
[41]Thommen Daniela S.,Koelzer Viktor H.,Herzig Petra,etc.
A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade
[J].2018,24(7).
[42]Enrico Munari,Giuseppe Zamboni,Gianluigi Lunardi,etc.
PD-L1 Expression Heterogeneity in Non–Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections
[J].2018,13(8).
[43]Caponnetto, Salvatore,Iannantuono, Giovanni Maria,Barchiesi, Giacomo,etc.
Prolactin as a Potential Early Predictive Factor in Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab
[J].2017,93(1).
[44]Brochez, Lieve,Chevolet, Ines,Kruse, Vibeke.
The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy
[J].2017,76.
[45].
3O Applicability of the lung immune prognostic index (LIPI) in patients with metastatic solid tumors when treated with immune checkpoint inhibitors (ICI) in early clinical trials.
[J].2019,30.
[46]Inomata, Minehiko,Kado, Tomonobu,Okazawa, Seisuke,etc.
Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor
[J].2019,39(12).
[47]Romualdo, Barroso-Sousa,William T, Barry,Ana C, Garrido-Castro,etc.
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
[J].2017,(Spec ).
[48]West, Howard,McCleod, Michael,Hussein, Maen,etc.
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 tria
[J].2019,20(7).
[49]Anton, Uryvaev,Maria, Passhak,Dov, Hershkovits,etc.
The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma.
[J].2018,35(3).
[50]Kowanetz, Marcin,Zou, Wei,Gettinger, Scott N.,etc.
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1)
[J].2018,115(43).
[51]Minglei, Zhuo,Hanxiao, Chen,Tianzhuo, Zhang,etc.
The potential predictive value of circulating immune cell ratio and tumor marker in atezolizumab treated advanced non-small cell lung cancer patients.
[J].2018,(Spec ).
[52]Jiang, Tao,Qiao, Meng,Zhao, Chao,etc.
Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysis
[J].2018,67(5).
[53]Andrea,Botticelli,Bruna,Cerbelli,Luana,Lionetto,etc.
Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
[J].2018,16(1).
[54]Baraibar, Iosune,Melero, Ignacio,Ponz-Sarvise, Mariano,etc.
Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer
[J].2019,42(2).
[55]Goldberg, Sarah B.,Narayan, Azeet,Kole, Adam J.,etc.
Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA
[J].2018,24(8).
[56]Jeong-Sun,Seo,Ahreum,Kim,Jong-Yeon,Shin,etc.
Comprehensive analysis of the tumor immune micro-environment in non-small cell lung cancer for efficacy of checkpoint inhibitor.
[J].2018,8(1).
[57]Dina M,El-Guindy,Duaa S,Helal,Nesreen M,Sabry,etc.
Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
[J].2018.
[58]Biagio,Ricciuti,Sasha,Kravets,Suzanne E,Dahlberg,etc.
Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.
[J].2019,7(1).
[59]Borghaei, H.,Paz-Ares, L.,Horn, L.,etc.
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
[J].2015,373(17).
[60]Miyuki,Sato,Satoshi,Watanabe,Hiroshi,Tanaka,etc.
Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations.
[J].2019,14(4).
[61]EGhorani,RRosenthal,NMcGranahan,etc.
Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma
[J].2018,29(1).
[62]Matthieu,Dusselier,Elise,Deluche,Nellie,Delacourt,etc.
Neutrophil-to-lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-treated patients with advanced non-small-cell lung cancers.
[J].2019,14(7).
[63]Maymani, Hossein,Hess, Kenneth,Groisberg, Roman,etc.
Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials
[J].2018,120.
[64]Takahiro Karasaki,Kazuhiro Nagayama,Hideki Kuwano,etc.
An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer
[J].2017,12(5).
[65]Gettinger, Scott,Choi, Jungmin,Hastings, Katherine,etc.
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
[J].2017,7(12).
[66]Herbst, Roy S.,Baas, Paul,Kim, Dong-Wan,etc.
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
[J].2016,387(10027).
[67]Albiges, Laurence,Richard, Corentin,Zitvogel, Laurence,etc.
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
[J].2018,359(Jan.5 TN.6371).
[68]Chu, Q.,Leighl, N.,Lonescu, D.,etc.
Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC
[J].2018,65.
[69]Brahmer, Julie,Reckamp, Karen L.,Baas, Paul,etc.
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
[J].2015,373(2).
[70]Gao, Shugeng,Li, Ning,Gao, Shunyu,etc.
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
[J].2020,15(5).
[71]Reck, Martin,Rodriguez-Abreu, Delvys,Robinson, Andrew G.,etc.
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
[J].2016,375(19).
[72]Siegel Rebecca L.,Miller Kimberly D.,Jemal Ahmedin.
Cancer statistics, 2020
[J].2020,70(1).
[73]Garon, Edward B.,Rizvi, Naiyer A.,Hui, Rina,etc.
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
[J].2015,372(21).
[74]Sakata, Yoshihiko,Kawamura, Kodai,Ichikado, Kazuya,etc.
The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment
[J].2019,130.
[75]Fehrenbacher, Louis,Spira, Alexander,Ballinger, Marcus,etc.
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
[J].2016,387(10030).
[76]Arbour, Kathryn C.,Riely, Gregory J..
Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer A Review
[J].2019,322(8).
[77]Chowell, Diego,Morris, Luc G. T.,Grigg, Claud M.,etc.
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
[J].2018,359(Feb.2 TN.6375).
[78].
T‐cell exhaustion interrelates with immune cytolytic activity to shape the inflamed tumor microenvironment
[J].2020,251(2).
[79]Csoszi, T.,Gumus, M.,Rodriguez-Cid, J.,etc.
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
[J].2018,379(21).
[80]Wang, Zhijie,Duan, Jianchun,Cai, Shangli,etc.
Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel
[J].2019,5(5).
[81].
Transcriptome-based molecular subtyping of non-small cell lung cancer may predict response to immune checkpoint inhibitors
[J].2020,159(4).
[82]Takada Kazuki,Yoneshima Yasuto,Tanaka Kentaro,etc.
Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors
[J].2020,146(5).
[83]Chung, Hyun Cheol,Piha-Paul, Sarina A.,Lopez-Martin, Jose,etc.
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies
[J].2020,15(4).
[84]Nakazawa Nobuhiro,Yokobori Takehiko,Kaira Kyoichi,etc.
High Stromal TGFBI in Lung Cancer and Intratumoral CD8-Positive T Cells were Associated with Poor Prognosis and Therapeutic Resistance to Immune Checkpoint Inhibitors
[J].2019,27(3).
[85]Karthik Suresh,Khinh Ranh Voong,Bairavi Shankar,etc.
Pneumonitis in Non–Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors
[J].2018,13(12).
[86]Hoy Sheridan M..
Sintilimab: First Global Approval
[J].2019,79(3).
[87]Landre, Thierry,Guetz, Gaetan Des,Chouahnia, Kader,etc.
First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or < 1; PD-L1-expressing metastatic non-small-cell lung cancers
[J].2020,146(2).
[88]A N,Niemeijer,D,Leung,M C,Huisman,etc.
Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer.
[J].2018,9(1).
[89]Karantanos, T.,Karanika, S.,Seth, B.,etc.
The absolute lymphocyte count can predict the overall survival of patients with non-small cell lung cancer on nivolumab: a clinical study
[J].2019,21(2).
[90]Schett, Anne,Rothschild, Sacha I.,Curioni-Fontecedro, Alessandra,etc.
Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors: Antibiotics immune checkpoint inhibitors in advanced NSCLC
[J].2020,85(1).
[91]Hersom, Maria,Jorgensen, Jan T..
Companion and Complementary Diagnostics-Focus on PD-L1 Expression Assays for PD-1/PD-L1 Checkpoint Inhibitors in Non-Small Cell Lung Cancer
[J].2018,40(1).
[92]Ready, Neal E.,Ott, Patrick A.,Hellmann, Matthew D.,etc.
Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort
[J].2020,15(3).
[93]Ready, Neal,Farago, Anna F.,de Braud, Filippo,etc.
Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
[J].2019,14(2).
[94]Jun Yeun Cho,Junghoon Kim,Jong Seok Lee,etc.
Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer
[J].2018,125.
[95]Tatsunori,Kiriu,Masatsugu,Yamamoto,Tatsuya,Nagano,etc.
Prognostic Value of Red Blood Cell Distribution Width in Non-small Cell Lung Cancer Treated With Anti-programmed Cell Death-1 Antibody.
[J].2019,33(1).
WanfangData CO.,Ltd All Rights Reserved
About WanfangData
|
Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:
yiyao@wanfangdata.com.cn